흉터 치료 시장 : 치료 방법별, 흉터 유형별, 제품 형태별, 판매 채널별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Scar Treatment Market is projected to grow by USD 15.68 billion at a CAGR of 9.36% by 2032.

Executive Introduction to Scar Treatment

The scar treatment market is expanding as patients, clinicians, and payers place greater emphasis on functional recovery, appearance, and long-term quality of life after surgery, burns, trauma, acne, and inflammatory skin disease. Scar management spans topical silicone gels and sheets, corticosteroid injections, laser and energy-based devices, pressure therapy, cryotherapy, surgical revision, and combination protocols for hypertrophic scars, keloids, contractures, and atrophic acne scars.

Clinical guidance and dermatology practice consistently support early scar assessment, sun protection, silicone-based therapy for selected raised scars, and escalation to procedural care when scars cause pain, pruritus, restricted mobility, or psychosocial burden. Demand is reinforced by rising surgical volumes, higher awareness of minimally invasive aesthetic dermatology, and continued device innovation across fractional lasers, radiofrequency microneedling, ultrasound, and imaging-enabled treatment planning.

Transformative Shifts in Scar Treatment

The scar treatment landscape is shifting from single-modality correction toward evidence-informed, combination-based protocols. Dermatologists and plastic surgeons increasingly pair silicone therapy, intralesional corticosteroids or 5-fluorouracil, laser resurfacing, microneedling, pressure therapy, and surgical revision based on scar type, skin phototype, wound age, anatomic location, and recurrence risk. This shift supports better personalization, especially for keloids and hypertrophic scars that can recur after excision alone.

Another major transformation is the movement from purely cosmetic positioning to medically meaningful outcomes. Scar treatment is now evaluated through pliability, pigmentation, vascularity, thickness, pain, itching, range of motion, contracture release, and patient-reported quality of life. This broader outcomes framework is influencing product development, payer discussions, clinical trial endpoints, and procurement decisions in hospitals, dermatology clinics, burn centers, and aesthetic practices.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to reshape scar treatment by improving image capture, scar classification, severity scoring, and longitudinal monitoring. AI-enabled imaging can support objective assessment of erythema, pigmentation, surface texture, and volume change, reducing dependence on subjective visual grading alone. These tools are especially relevant for multicenter clinical studies, teledermatology follow-up, burn rehabilitation, and practices managing high volumes of acne scars, surgical scars, and traumatic scars.

The cumulative impact of AI is expected to be operational as much as clinical. Predictive analytics can help identify patients at higher risk of hypertrophic scarring or keloid recurrence based on clinical history, wound characteristics, and skin type, while decision-support tools may guide timing, modality selection, and follow-up intervals. AI also strengthens patient engagement by enabling standardized before-and-after documentation, adherence reminders, remote progress tracking, and more consistent communication of realistic outcomes.

Key Regional Insights for Scar Treatment

In Asia-Pacific, scar treatment demand is supported by large patient populations, rising dermatology access, growth in medical aesthetics, high acne burden, and greater awareness of post-surgical and post-burn scar correction across China, India, Japan, South Korea, Australia, and Southeast Asia. North America remains a high-adoption region due to mature dermatology networks, availability of advanced laser and energy-based platforms, high procedure awareness, established burn care pathways, and strong participation in clinical research.

Latin America shows steady demand driven by aesthetic medicine growth in Brazil and Mexico, broader access to private dermatology, and continued interest in acne scar and surgical scar revision. Europe benefits from regulated medical device adoption, established burn and reconstructive care systems, and strong dermatology expertise across major markets, with evidence requirements shaping product uptake. The Middle East is gaining traction through private specialty clinics, high demand for aesthetic procedures, and medical tourism in GCC countries, whereas Africa represents an emerging opportunity where access, affordability, burn care capacity, wound care infrastructure, and clinician training remain central to market development.

Key Group Insights Across Global Markets

ASEAN markets are advancing as private dermatology and aesthetic clinics expand in urban centers, with acne scar correction, post-procedure scar care, and accessible topical scar products as key demand drivers. The GCC benefits from high private healthcare expenditure, medical tourism, and patient preference for premium dermatology technologies, creating opportunities for laser systems, silicone products, injectable therapies, and physician-led combination protocols.

The European Union emphasizes regulatory compliance, clinical evidence, patient safety, and standardized medical device pathways, which support high-quality product adoption but require strong documentation and post-market surveillance. BRICS countries represent scale-driven opportunity, led by large surgical, trauma, burn, and acne patient bases, rising private healthcare access, and expanding dermatology capacity. G7 markets are characterized by advanced procedural adoption, innovation funding, specialist density, and higher demand for validated clinical and patient-reported outcomes. NATO countries overlap significantly with mature healthcare systems where procurement standards, clinician training, rehabilitation pathways, and evidence-based protocols influence adoption.

Key Country Insights in Scar Treatment

The United States leads in advanced dermatology procedures, clinical research, scar revision techniques, and adoption of laser resurfacing, radiofrequency microneedling, injectables, and silicone-based scar products, while Canada shows demand aligned with specialist access, burn care quality, and evidence-based care. Mexico and Brazil are important Latin American markets where aesthetic medicine, plastic surgery activity, and urban private care support scar revision demand, particularly for acne scars, surgical scars, and hypertrophic scars.

The United Kingdom, Germany, France, Italy, and Spain benefit from established dermatology, plastic surgery, and reconstructive care infrastructure, though reimbursement and public-private access vary by country and procedure type. Russia maintains demand in urban specialty practices with interest in laser-based and topical scar management. China and India offer large-scale opportunity due to population size, surgical volume, burn and trauma incidence, acne prevalence, and expanding private dermatology networks. Japan, South Korea, and Australia are characterized by high clinical standards, strong device uptake, developed aesthetic medicine sectors, and patient interest in minimally invasive skin quality improvement, while South Korea also benefits from high procedural familiarity and strong consumer awareness of dermatologic innovation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically differentiated products that align with scar type, treatment stage, and measurable outcomes. Organizations can strengthen competitiveness by investing in silicone formulations, combination therapy evidence, energy-based device optimization for diverse Fitzpatrick skin types, scar prevention protocols after surgery, and patient-friendly adherence features such as wearability, comfort, ease of use, and digital reminders.

Commercial teams should build education-led strategies for dermatologists, plastic surgeons, burn specialists, wound care teams, and aesthetic practitioners. Strong post-market evidence, real-world outcome tracking, inclusive clinical data across skin phototypes, standardized imaging, and AI-enabled documentation can improve trust, support premium positioning, and reduce variability in treatment protocols. Leaders should also tailor access strategies by region, balancing advanced procedural offerings in mature markets with affordable topical, silicone, and training-led solutions in emerging healthcare systems.

Research Methodology

The research methodology integrates secondary research from dermatology guidelines, peer-reviewed clinical literature, regulatory databases, public health sources, healthcare utilization indicators, product portfolios, patent activity, and treatment pathway analysis. Interpretation is supported by analysis of treatment modalities, end users, scar types, regional access, technology adoption, clinical evidence strength, reimbursement considerations, and competitive positioning.

Primary validation is conducted through structured discussions with stakeholders across dermatology, plastic surgery, medical aesthetics, burn care, wound care, distribution, procurement, and medical device commercialization. Insights are triangulated through data consistency checks, regional benchmarking, clinical evidence review, regulatory assessment, and evaluation of demand drivers, restraints, opportunities, and technology trends relevant to scar treatment.

Conclusion

Scar treatment is evolving into a more personalized, outcomes-driven category where topical products, injectables, procedures, rehabilitation, and digital tools work together across the patient journey. Adoption is supported by higher surgical and aesthetic procedure volumes, rising awareness of acne scar correction, better burn and trauma recovery pathways, and increasing recognition of the physical, functional, and psychosocial burden of scars.

The strongest opportunities will come from evidence-backed solutions that improve function, appearance, comfort, adherence, and recurrence control. Organizations that combine clinical validation, inclusive patient data, AI-enabled monitoring, standardized outcome measurement, and region-specific access strategies will be best positioned to lead in scar treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Scar Treatment Market, by Treatment Type

• 7.1. Injectable Treatment
  • 7.1.1. Corticosteroid Injection
  • 7.1.2. Dermal Fillers
• 7.2. Laser Treatment
  • 7.2.1. Co2 Laser
  • 7.2.2. Erbium Laser
  • 7.2.3. Fractional Laser
• 7.3. Surgical Treatment
  • 7.3.1. Dermabrasion
  • 7.3.2. Excision
  • 7.3.3. Skin Grafting
• 7.4. Topical Treatment
  • 7.4.1. Creams & Ointments
  • 7.4.2. Silicone Gel
  • 7.4.3. Silicone Sheet

8. Scar Treatment Market, by Scar Type

• 8.1. Atrophic Scar
• 8.2. Contracture Scar
• 8.3. Hypertrophic Scar
• 8.4. Keloid Scar

9. Scar Treatment Market, by Product Form

• 9.1. Cream
• 9.2. Device
• 9.3. Gel
• 9.4. Ointment
• 9.5. Sheet

10. Scar Treatment Market, by Distribution Channel

• 10.1. E Commerce Channel
  • 10.1.1. Direct E Commerce
  • 10.1.2. Distributor E Commerce
• 10.2. Hospital Channel
• 10.3. Pharmacy Channel

11. Scar Treatment Market, by End User

• 11.1. Clinics
• 11.2. Home Care
• 11.3. Hospitals

12. Scar Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Scar Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Scar Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 3M Company
• 16.2. Alliance Pharma plc
• 16.3. Avita Medical, Inc.
• 16.4. B. Braun Melsungen AG
• 16.5. Beiersdorf AG
• 16.6. BMG Pharma S.p.A.
• 16.7. Candlewood Pharmaceuticals, Inc
• 16.8. CCA Industries, Inc.
• 16.9. Coloplast A/S
• 16.10. ConvaTec Group plc
• 16.11. Cutera, Inc.
• 16.12. Galderma S.A.
• 16.13. Kerecis ehf.
• 16.14. Laboratoires Expanscience S.A.
• 16.15. Merz Pharma GmbH & Co. KGaA
• 16.16. Molnlycke Health Care AB
• 16.17. Neodyne Biosciences, Inc.
• 16.18. Perrigo Company plc
• 16.19. Revitol Corporation
• 16.20. Scapa Healthcare Limited
• 16.21. Silagen, Inc.
• 16.22. Sinclair Pharma Limited
• 16.23. Smith & Nephew plc
• 16.24. Sonoma Pharmaceuticals, Inc.
• 16.25. Stratpharma AG